ArticleJournal of cardiovascular medicine (Hagerstown, Md.)2025
Efficacy and safety of apical access in percutaneous pericardiocentesis: a comparison with subxiphoid approach.
Article in Journal of cardiovascular medicine (Hagerstown, Md.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Pericardio-peritoneal communication following emergency subxiphoid pericardiocentesis in acute complex percutaneous coronary intervention: a case report.European heart journal. Case reports · 2026Article
- Iatrogenic Large Bowel Perforation Following Image-Guided Pericardiocentesis: A Case Report.The American journal of case reports · 2026Article
- Long-term mortality and acute complications after percutaneous pericardiocentesis in cancer and noncancer patients presenting with severe pericardial effusion.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimPercutaneous pericardiocentesis represents the sole curative intervention for significant pericardial effusion, especially in cardiac tamponade. While the subxiphoid route is traditionally the most utilized, alternative approaches - such as the apical access - have also been adopted. To date, no studies have directly compared the performance, risk profile, and clinical implications of these techniques. This study aims to evaluate and compare the effectiveness, complication rates, and short- to medium-term outcomes of apical versus subxiphoid pericardiocentesis. MATERIALS AND
methodsWe performed a retrospective analysis of pericardiocentesis procedures carried out at the Cardiac Intensive Care Unit of the IRCCS San Gerardo dei Tintori Foundation in Monza, Italy, between January 2011 and December 2024. Patients were categorized based on the access site: apical or subxiphoid.
resultsAmong 199 procedures, 85 (42.7%) were performed via the subxiphoid route and 114 (57.3%) through apical access. Most interventions addressed acute tamponade or pretamponade states. Imaging guidance was employed in 89.6% of cases. Baseline demographics, comorbidities, and echocardiographic features were comparable between the two groups. The overall success rate was 98.5%, with no significant differences between approaches. Major complications were rare (0.5%), and minor complications occurred in 11.1% of cases, without notable variance between techniques. Patient outcomes - including overall survival, in-hospital survival, and pericardiocentesis-free survival - showed no statistically significant differences (median follow-up: 17.2 months; interquartile range: 3.8-69.2 months).
conclusionsApical access for percutaneous pericardiocentesis demonstrates similar efficacy and safety to the subxiphoid approach, representing a valid alternative in appropriate clinical contexts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.